Psoriasis is a chronic immune-mediated disease in which the interleukin IL -23/IL-17 axis plays a key role in the inflammatory cascade. We recently reported that co-expression of CCR6 and melanoma cell adhesion molecule MCAM in effector memory CD4 T cells T EM of peripheral blood might be a useful marker for T helper Th 17 cells. In this study, we monitored changes in T EM expressing CCR6 and MCAM using the Psoriasis Area and Severity Index PASI score during anti-tumor necrosis factor TNF therapy. We also studied CCR6 MCAM Th17 cells histologically in skin biopsy samples from psoriasis patients. In psoriasis patients treated with anti-TNF therapy, the PASI score and the percentage of CCR6 MCAM T EM cells in the blood changed almost in parallel. In immunohistochemical analyses, the proportions of IL-17 T cells and MCAM T cells in the lesional skin of severely psoriatic patients were signi cantly higher than in mildly psoriatic patients P 0.05 , and the number of IL17 T cells correlated with the PASI score r 0.400, P 0.05 . Taken together, these results indicate that CCR6 MCAM Th17 cells in peripheral blood and lesional skin might play an important role in the pathology of psoriasis.
Introduction
Psoriasis is a chronic immune-mediated disease that affects [2] [3] [4] of the general population worldwide [1] [2] [3] . Over the past two decades, increased research into the physiopathology of psoriasis has resulted in novel therapeutic options [4] [5] [6] . T helper Th 17 cells have been shown to play a key role in the in ammatory cascade central to the disease, via the so-called interleukin IL -23 / IL-17 axis [7] [8] . Accordingly, psoriasis is sensitive to biological agents targeting IL-17 and IL-23 [9] [10] [11] .
Effector memory CD4 T cells T EM migrate into in amed tissues, produce various cytokines, and aggravate psoriasis 12 . In addition, Th17 cells, a subset of CD4 T helper cells, characteristi-cally secrete cytokines such as IL-17 and play important roles in the pathogenesis of several inflammatory and autoimmune diseases 13 . Although several cell surface markers for human Th17 cells have been reported including CCR6, MCAM, and CD161 [14] [15] [16] , none has demonstrated practical utility in determining the severity of psoriasis. For example, although Th17 expresses CCR6 13 , this is not a reliable clinical marker of psoriasis.
The CD146 / melanoma cell adhesion molecule MCAM or MUC18 belongs to the immunoglobulin superfamily, and has been identi ed initially as a useful marker of melanoma progression and metastasis 17 . In normal adult tissues, MCAM is expressed primarily by vascular endothelium and smooth muscle, where it plays roles in cellular adhesion. MCAM was also reported to be a marker of activated T cell groups that are enriched in T EM 18 , and to aid the migration of Th17 cells into the central nervous system of patients with multiple sclerosis 14 . Previously, we reported that CCR6 MCAM T EM produced more IL-17 than other T EM subsets in a study designed to clarify whether the CCR6 MCAM phenotype could identify pathogenic Th17 cells in patients with psoriasis 19 . In the present study, CCR6 MCAM T EM , that enriches Th17 cells in both peripheral blood and CCR6 MCAM IL-17 CD4 T cells in lesional skin, seemed to correlate with psoriatic disease severity. We also discuss the pathogenic roles played by these markers in the Th17 cell-mediated responses to disease.
Materials and methods

Patients Blood samples from healthy controls and psoriatic patients
We studied two naïve patients with psoriasis vulgaris who were treated with anti-TNF therapy infliximab at Showa University Hospital. Before and after treatment, we collected blood samples and determined the Psoriasis Area and Severity Index PASI scores to evaluate the severity of psoriasis.
Skin samples from psoriatic patients
We obtained skin samples from 34 patients 21 males, 13 females, aged 21-87 years ; mean age, 59.2 years newly diagnosed with psoriasis vulgaris in the Department of Dermatology at Showa University Hospital from 2010 to 2014. Medical records were also reviewed to extract clinical information and laboratory data. We divided the patients into two groups : those with mild PASI 12 and severe PASI ≥ 12 disease. The mean PASI score was 11.7 ; the mean scores of the mild and severe groups were 4.97 0.60 mean SEM and 19.3 1.07, respectively.
Written informed consent to participate in the study was obtained from all patients. The Ethics Committee of Showa University School of Medicine approved this study.
Flow cytometric analysis
Peripheral mononuclear blood cells PMBCs in phosphate-buffered saline PBS with 0.2 w / v bovine serum albumin BSA were incubated on ice for 30 min with the following murine monoclonal antibodies against human antigens 50-fold dilutions : Paci c Blue anti-CD3 clone OKT3 , Brilliant Violet 510 anti-CD4 clone OKT4 , PerPC / Cy5.5TM anti-CD45RA clone HI100 , Alexa Fluor 488 anti-CCR7, PE / Cy7TM anti-CCR6 clone G034E3 , and PETM anti-MCAM clone P1H12 . All anti-human protein antibodies used in ow cytometry were purchased from BioLegend San Diego, CA, USA . Cells were washed twice with ice-cold PBS containing 0.2 w / v BSA. After ltration, cells were analyzed using a FACSAria II running the FACS Diva software ver. 6.1 ; BD Biosciences, San Jose, CA, USA .
Immunohistochemistry
Immunohistochemical analysis was performed on 3 µm sections from formalin-fixed, paraffin wax-embedded specimens, using antibodies against the following proteins : CD3 clone PS1, Novocastra, Newcastle, UK , CD4 clone 1F6, Novocastra , CD8 clone C8 / 144B, DakoCytomation A / S, Glostrup, Denmark , CD146 / MCAM clone EPR3028, Millipore Bedford, MA, USA , CCR6 clone 53103, R&D , and IL-17 polyclonal, goat ; LifeSpan Biosciences, Seattle, WA, USA .
Evaluation of immune cells detected microscopically
We determined the percentages of CCR6 cells in CD3 T cells, and the percentages of IL17 and MCAM cells in 300 CD3 T cells in tissue sections 400 .
Statistical analysis
Paired or unpaired two-tailed Student s t-tests were used to compare differences between groups. A P-value of 0.05 was considered to indicate statistical signi cance. Spearman s ordered correlation coef cients were calculated.
Results
The percentage of CCR6 MCAM T EM cells paralleled the PASI score in psoriasis patients treated with biologics
The PASI scores and percentages of CCR6 MCAM T EM cells in seven psoriasis patients who were treated with biologics, such as in iximab, adalimumab, and ustekinumab Table 1 , were monitored. Six patients responded to the treatments and showed decreases in both PASI scores and percentages of CCR6 MCAM T EM cells. One patient no. 5 in Table 1 was worse clinically after the treatments and the PASI scores and percentages of CCR6 MCAM T EM cells were still increased. Fig. 1 shows a typical case of parallel changes in PASI scores and percentages of CCR6 MCAM T EM cells during treatment for psoriasis. The patient was treated with in iximab and responded transiently, and then the treatment was changed to adalimumab. Subsequently, the symptoms improved. Whether the shift was up or down, all changes in PASI score and the percentage of CCR6 MCAM T EM were almost in parallel. These results suggest that percentages of CCR6 MCAM T EM in peripheral blood re ected the therapeutic response.
Localization of T cells and expression of cellular markers in psoriasis and the examination of CCR6 MCAM IL-17 cells by IF microscopy
In psoriatic lesional skin, most CD3 T cells including CD4 cells and CD8 cells were localized to certain regions of the upper dermis Fig. 2a, b , c ; such accumulations of skinin ltrating T cells are often observed in the perivascular areas of psoriatic lesional skin 20 . Large numbers of CCR6 cells as well as CD4 cells were present in the same area Fig. 2d , as well as some IL-17 cells and CCR6 cells Fig. 2e , f .
We performed double staining to evaluate the consistency in numbers of CD4 , CCR6 MCAM , IL-17 MCAM , and CCR6 IL-17 cells among patients and controls. As shown in Fig. 2g , h, antibodies to MCAM red and IL-17 green , or antibodies to MCAM green and CCR6 red , stained CD4 cells in the upper dermis. We concluded that the large MCAM CD4 cells were not of the macrophage lineage, because they were negative for CD68 data not shown , and cells of the myeloid lineage do not express MCAM 15 . These data suggest that CCR6 MCAM Th17 cells were present in the lesional skin of patients with psoriasis. Because CCR6 and MCAM are both involved in the migration of in ammatory T cells 14 18 , the elevated numbers of CCR6 MCAM T EM cells in peripheral blood may migrate to lesional skin.
Correlations between IL-17 and MCAM cell numbers in lesional skin and the severity of psoriasis
We calculated the percentages of IL17 cells among 300 CD3 T cells evident in tissue sections, and compared these numbers to the disease severity in 34 psoriasis patients. A signi cant difference was evident between patients with mild PASI 12 and severe PASI ≥ 12 disease Fig. 3a . Moreover, we found a signi cant correlation between the PASI score and IL17 cell numbers r 0.400 ; Fig. 3b . Next, we determined the proportions of MCAM cells among CD3 cells in psoriatic lesional skin, and found signi cantly higher proportions of MCAM cells in the severe disease group than in patients with mild disease Fig. 3c . There was also a moderate and signi cant correlation between the PASI score and MCAM cell numbers r 0.42 ; Fig. 3d .
Discussion
A recent study found that the number of circulating MCAM CD4 T cells was increased in patients with in ammatory autoimmune diseases, including Behçet s disease, sarcoidosis, and Crohn s disease, and that such numbers are correlated with disease severity 21 . Moreover, anti-MCAM antibody therapy seemed to be potentially effective for the treatment of various Th17mediated diseases 22 , suggesting that MCAM could play pathogenic roles in disease. Indeed, the MCAM level in endothelial cells is increased by TNF, and it acts to enhance both angiogenesis and migration of activated monocytes into in amed tissues, suggesting that MCAM may augment the pathogenesis of psoriasis 18 . As shown in Table 1 and Fig. 1 , the percentages of CCR6 MCAM T EM cells in the blood re ected the therapeutic response in parallel with PASI scores, supporting the notion of MCAM with a speci c pathological role. Thus, Th17 subtypes expressing MCAM might augment disease pathogenesis. However, the number of patients tested in this study was low, and studies using more patient are needed.
In this study, we showed that CCR6 MCAM Th17 cells were present in psoriatic lesional skin and were more numerous in the peripheral blood of affected patients than in healthy controls. Although circulating Th17 cells can be recruited into lesional skin by CCR6 and MCAM, the source of the circulating Th17 cells remains unknown, and there are at least two possibilities. One is that in ammatory dendritic cells in lesional skin migrate into lymph nodes and drive Th17 cells produced in the lymph nodes into the circulation. Another is that Th17 cells produced by in ammatory dendritic cells in lesional skin return to the circulation. Because human adult naïve CD4 T cells have not been shown to develop into Th17 cells unlike Th1 or Th2 cells 23 24 , the latter possibility seems attractive. However, the former one is supported by the observation that in ammatory dendritic cells positive for IL-1 , IL-23, and CCR7 are present in psoriatic lesional skin unpublished data .
In conclusion, we showed that CCR6 MCAM T EM cells are enriched in the Th17 cells of peripheral blood of psoriasis patients, and that the numbers of CCR6 MCAM Th17 cells in lesional skin may correlate with disease severity. Moreover, the percentage of CCR6 MCAM T EM cells in the blood of psoriasis patients re ects the therapeutic response, and it could be a useful marker of the disease process. Our results contribute to a better understanding of the relationships between Th17 responses and the pathogenesis of psoriasis.
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